Premium
Activating point mutations in the β C chain of the GM‐CSF, IL‐3 and IL‐5 receptors are not a major contributory factor in the pathogenesis of acute myeloid leukaemia
Author(s) -
Freeburn Robin W.,
Gale Rosemary E.,
Linch David C.
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.00939.x
Subject(s) - point mutation , receptor , pathogenesis , biology , mutant , mutation , myeloid , allele , genetics , gene , immunology , microbiology and biotechnology , cancer research
A number of mutant growth factor receptors have been described which are constitutively activated and confer factor independence on growth factor dependent cells, possibly through constitutive dimerization in the absence of ligand or induction of a conformational change. Mutations in receptor chains may therefore contribute to the pathogenesis of haemopoietic malignancies, for example by causing constitutive receptor activation or uncontrolled downstream signalling. Since most of the activated mutants reported for the β C chain of the GM‐CSF/IL‐3/IL‐5 receptor involve point mutations or truncations of the extracellular domain, we have analysed the coding sequence of this region using RT‐PCR‐SSCP of RNA from blast cells of 31 patients with acute myeloid leukaemia (AML). Two point mutations detected were silent, C 301 → T (Cys91) and C 1306 → T (Ser426). The latter had previously been identified with an allele frequency of 0.13 in the general population. Two further point mutations detected led to amino acid substitutions, G 773 → C (Glu249Gln), which is equivalent to the mouse sequences, and G 962 → A (Asp312Asn), both of which were found at similar frequencies in normal controls. Activating mutations of the β C chain which might contribute to the pathogenesis of the disease are therefore rare in AML.